NCT02167854 2021-07-09
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
4 trialsNCT01598077 2020-12-19
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Novartis
Phase 1 Completed
NCT01602406 2020-12-19
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Novartis
Phase 1 Completed
NCT01822613 2020-12-19
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Novartis
Phase 1 Completed